China NMPA Drug Inspection - Guilin Zhongnan (Bozhou) Pharmaceutical Technology Co., Ltd. - Purple gromwell
China NMPA drug inspection for Guilin Zhongnan (Bozhou) Pharmaceutical Technology Co., Ltd. published August 29, 2022. Drug: Purple gromwell. In August 2022, the National Medical Products Administration (NMPA) issued Announcement No. 39, identifying 20 batches o
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Guilin Zhongnan (Bozhou) Pharmaceutical Technology Co., Ltd. published August 29, 2022. Drug: Purple gromwell. In August 2022, the National Medical Products Administration (NMPA) issued Announcement No. 39, identifying 20 batches o
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox